Marketresearchnews

Friday, 6 December 2019

Smart Biosensors Market - Granular Market Report and Review, 2019

Market Scenario:

Biosensors are analytical devices used for detection of chemical and biological substances in the human body. Smart biosensors are easy to use, simple, accurate and effective than traditional methods of analysis. Biosensors are becoming popular in developed countries. The increasing prevalence of diabetes in emerging economies, demand for advanced monitoring systems, and increasing awareness about advance biosensors are expected to drive the growth of the market. According to the report published by World Health Organization(WHO) in 2016, diabetes is a major healthcare concern in Brazil, and it affected more than 8.1% of the population, the prevalence of diabetes was more in females, and it affected more than 8.8% females in the country. Moreover, rising R&D spending and collaborative strategies adopted by the top players such as new product launches and collaborations for product development are contributing to the growth of the market.

Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/7801

The Global Smart Biosensors Market accounted for USD 12000 million and expected to register 7.64% CAGR during the forecast period (2018–2023)

The rising cost of biosensors and unfavorable reimbursement policies may hamper the growth of the market during the assessment period.

Top Key Players

Abbott Point of Care Inc.,
Medtronic Inc.,
Hoffman La-Roche Ltd.,
Siemens Healthcare AG,
Lifescan, Inc.,
LifeSensors Inc.,
Nova Biomedical Corp.,
Acon Laboratories Inc.,
Universal Biosensors,
Pharmaco-Kinesis Corporation,
Segmentation

The global smart biosensors market has been segmented on the basis of product type, technology, application, and end user.

On the basis of product type, the market has been classified as wearable biosensors, non-wearable biosensors.

The technology segment has been divided into electrochemical biosensors, piezoelectric biosensors, optical biosensors, thermal biosensors, nanomechanical biosensors, and others. thermal biosensors segment is likely to be the fastest growing segment during the forecast period.

The market, by application, has been segmented into blood glucose testing, cholesterol testing, blood gas analysis, pregnancy testing, drug discovery, infectious disease testing, and others.

The end user segment has been divided into point-of-care, home diagnostics, research labs, security & biodefense, environmental monitoring, food & beverage industry, and others

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The smart biosensors market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European smart biosensors market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The smart biosensors market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The smart biosensors market in the Middle East & Africa has been segmented into the Middle East and Africa.

Regional Market Summary

The Americas are expected to hold the maximum share of global smart biosensors market owing to the rising prevalence of chronic disorders, favorable policies implemented by government and regulatory authorities, and adoption of highly advanced technology. According to the article published in 2016 by National Council on Aging, the prevalence of Chronic disorders in American regions is continuously increasing and about 80 percent of older adults have at least one chronic disease, and more than 68 percent were suffering from more than one chronic disorders.

The European market is likely to be the second-largest smart biosensors market. The market growth in this region can be attributed to the presence of well-established healthcare system in the region, government initiatives for controlling chronic disorders, and increase in the population suffering from cardiovascular disorders. According to the European Heart Network, cardiovascular disorders are responsible for 3.9 million deaths in the European Union which are 45% of the total deaths.

Asia-Pacific is expected to be the fastest-growing smart biosensors market during the forecast period owing to the increasing prevalence of diabetes, increasing disposable income, and government initiatives for the development of the healthcare sector. According to the International Diabetes Federation, in 2017, more than 84 million people in South-East Asia were affected by diabetes, and this number is expected to reach 156 million by 2045.

The market in the Middle East & Africa is expected to hold the smallest share of the global smart biosensors market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.

Browse Premium Research Report Enabled with Tables and Figures at @ https://www.marketresearchfuture.com/reports/smart-biosensors-market-7801

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Mortuary Refrigerator Market Volume Forecast and Value Chain Analysis 2019

Mortuary refrigerators are used to keep dead bodies as a solution to maintain hygiene requirements in hospitals. The key factors contributing for the market growth are growing number of cancer patient and cancer-related research, increasing organ transplant, and growing demands for automation in mortuary procedures. Also, the increasing geriatric population, is contributing to drive the market. According to the United Census Bureau, the global-female-geriatric population is estimated to reach 4,139 million by 2030 from 3,601 million in 2015. However, the minimal awareness about mortuary equipment and fluctuating prices of raw materials and substituting products for mortuary refrigerators hinders the market growth.

There are several companies involved in manufacturing of mortuary refrigerators with advanced features and ease to use. However, the cost of mortuary refrigerators compare to other mortuary related products and presence of alternative products in the market are hindering the market growth.

Some of the key players in the global mortuary refrigerators market are LEEC (UK), Hygeco (Saint-Ouen, (UK)), Paragon scare Ltd. (London), Thalheimer Kühlung (UK), Barber Medical (UK), CEABIS (Italy), EIHF Isofroid (UK), EVERmed (Italy), and Fiocchetti and Funeralia (UK) and others.

Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/7437

The global mortuary refrigerator market is expected to register a CAGR of 4.3% during the forecast period of 2018 to 2023.

Mortuary refrigerators are the largely used equipment in the whole mortuary equipment market. These refrigerators have available with several features such as temperature adjustable knob, multiple chambers. Mortuary refrigerators are available in both positive and negative temperature facility. The positive temperature refrigerator slows down the degradation process of dead bodies for a period of time, and the negative temperature mortuary refrigerators are used to storage the body by freezing it and prevent degradation for longer duration. The increase in technology and rising demand for automation in mortuary procedures is one of the reasons for the larger share of the market.

Segmentation

The global mortuary refrigerator market is segmented on the basis of product type, application, application, end user, and region.

On the basis of product type, the market is segmented into positive temperature, negative temperature refrigerators.

By application, the market is categorised into corpses storage and forensic investigation. On the basis of end-user, the global mortuary refrigerator market is categorised into forensic labs, research and academics, funeral homes, hospitals and clinics, and others.

Regional Market Summary

The Americas dominates the global market for mortuary refrigerator owing to the increase in cancer and cancer-related research activities, increasing number of geriatric populations with health-related problems and presence of major market players within the region boosts the market growth. According to the Administration for Community Living in 2016, the number of older women within the region was estimated to be 26.7 million. Furthermore, the presence of developed economies and regulations by various authorities in healthcare sector within the region boosts the market growth.

In 2017, it was estimated that Europe stood second in the global mortuary refrigerator market. The increase in demand for mortuary refrigerator by forensic labs and hospitals to store the dead bodies for investigation increases the market growth. These equipment’s are also, used to store the entire body donated for medical research purpose, which are used in medical colleges to teach human anatomy.

Asia Pacific was the fastest growing region for the global mortuary refrigerator market in 2017. Factors such as increasing awareness about the advanced and innovative mortuary refrigerator, growing regulations and policies by various authorities regarding the hygiene in hospital drives the market growth.

On the other hand, the Middle East and Africa holds a least share in the global mortuary refrigerator market due to the lack of awareness about the advanced mortuary procedures and mortuary refrigerator hinders the market growth in this region.

Browse Complete 110 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/mortuary-refrigerator-market-7437

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Research Report and Overview on Leukemia Therapeutics Market, 2019

The clinical condition an in which an increased number of abnormal leucocytes or generally called white blood cells of malignant characteristic is called leukemia. Frequent infections, fever with chills and fatigue are early signs of leukemia. Acute, chronic, lymphocytic, and myelogenous leukemias are classified under leukemia. Cancer statistics center of American Cancer Society estimates 61780 new cases of leukemia in 2019. Treatment for such a malicious disease requires intense therapeutic attention. Therefore, the need for accurate treatment in the rising population of leukemia patients is the major factor impelling the global leukemia therapeutics market growth. The traditional therapies involved in the treatment of leukemia are chemotherapy, biological therapy, targeted therapy, radiation therapy, and stem cell transplant. The complex pathology of leukemia demands advancements in medical infrastructure for treatment. Hence, letting the market key players immense opportunity to invest in research and development and bring forth innovation in the leukemia therapy. This generates a lead for clinical researchers to investigate better drug administration methods. Efforts which are being made to deliver more effective leukemia therapies is likely to trigger the leukemia therapeutics market growth.

Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/7425

However, on the flip side, the high cost of existing leukemia therapies and investment required for developing new therapies is curbing the leukemia therapeutics market expansion.

Global leukemia therapeutics market is expected to grow significantly over the forecast period. It is anticipated that the market held the value of USD 10.7 billion in 2017 and is projected to grow at a CAGR of 5.3% during the assessment period predicts Market Research Future (MRFR).

Segmentation

The global leukemia therapeutics market has been segmented into type, applications, and region.

Based on applications, leukemia therapeutics market is segmented into acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and others. The acute lymphocytic leukemia segment is expected to account for the largest share segment of the market in 2017.

Based on type, leukemia therapeutics market is segmented into chemotherapy, biological therapy, targeted therapy, radiation therapy, and stem cell transplant. The chemotherapy segment is expected to account for the largest share segment of the market in 2017. Chemotherapy segment further sub segmented into alkylating agents, antimetabolites, antitumor antibiotics, and others.

Top Key Players

Eisai Co., Ltd (Japan)
Novartis AG (Switzerland)
Pfizer Inc. (US)
GlaxoSmithKline plc (UK)
Bristol-Myers Squibb Company (US)
Hoffmann-La Roche AG (Switzerland)
Sanofi S.A. (France)
Teva Pharmaceutical Industries Ltd (Israel)
Amgen Inc (US)
Takeda Pharmaceutical Company Ltd (Japan)

Regional Market Summary

Geographically, the Americas is anticipated to dominate the global leukemia therapeutics market owing to a well-established player, innovative therapies to drive the market for leukemia, increase prevalence of leukemia, and increasing older population.

Europe is expected to hold the second largest position in the global leukemia therapeutics market. The market growth in this region is attributed to increase prevalence of leukemia.

The leukemia therapeutics market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region.

The Middle East & Africa has the least share of the leukemia therapeutics market.

Browse Complete 110 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/leukemia-therapeutics-market-7425

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Plasma Fractionation Market 2019 Analysis, Opportunities and Forecast to 2023

Increasing prevalence of immunodeficiency disorders and rising healthcare expenditure are also boosting the plasma fractionation market in the US region. According to the 2018 study published in the Allergy, Asthma & Clinical Immunology journal, the estimated overall prevalence of immunoglobulin A (IgA) deficiency in the US was approximately 1 in 300 to 1 in 500 persons.

Rising participation of market players is one of the key factors driving the plasma fractionation market. For instance, in 2018, Grifols acquired 24 plasma donation centers in the United States operated by Biotest Pharmaceuticals Corp. for USD 286 million. With this acquisition, Grifols now owns 249 plasma donation centres to increase its supply of plasma proteins used for therapeutic purposes.

In plasma fractionation process protein products are fractionated from human plasma for the prevention, and treatment of life-threatening conditions such as congenital deficiencies, immunologic disorders, and others.

Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/7397

Global Plasma Fractionation Market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 18073 million in 2017 and is projected to grow at a CAGR of 6.5% over the forecast period.

Various other factors such as increasing geriatric population, technological advancements, emerging markets in APAC and RoW, rising plasma collection, and increasing prevalence of respiratory and autoimmune disorders are also expected to propel the growth of the market.

However, the emergence of recombinant alternatives, high cost of advanced products, and unfavourable reimbursement policies can hamper the market growth over the forecast period.

Segmentation

The global plasma fractionation market is segmented based on product, application, end user, and region.

The global market for plasma fractionation, by product is segmented into immunoglobulin, coagulation factor concentrates, albumin, protease inhibitors, and others. The immunoglobulin segment is further classified as intravenous immunoglobulin (IVIG), subcutaneous immunoglobulin (SCIG), and others. The coagulation factor concentrates segment is further classified as Factor VIII, Factor IX, Von Willebrand Factor, Prothrombin Complex Concentrate, Fibrinogen Concentrates, and Factor XIII.

Based on application, the market is segmented into immunology, neurology, hematology, critical care, pulmonology, rheumatology, hemato-oncology, and others.

Based on end user, the market is segmented into hospitals & clinics, clinical research laboratories, academic institutes, and others.

In the current scope of the study, the above-mentioned segments are covered into the four global regions, namely the Americas, Europe, Asia-Pacific and the Middle East & African region.

The plasma fractionation market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European plasma fractionation market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The plasma fractionation market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The plasma fractionation market in the Middle East & Africa has been segmented into the Middle East and Africa.

Regional Market Summary

The Americas dominated the global market for plasma fractionation owing to the presence of major market players and increasing prevalence of immunodeficiency disorders within the region. According to the 2018 study published in the Allergy, Asthma & Clinical Immunology journal, the estimated overall prevalence of immunoglobulin A (IgA) deficiency in the US was approximately 1 in 300 to 1 in 500 persons.

In 2017, it was estimated that Europe stood second in the global plasma fractionation market. This can be attributed to the increasing technological advancements, and rising R&D investments.

Asia Pacific was projected to be the fastest growing region in 2017. Increasing healthcare expenditure drives the regional markets of the Asia Pacific region. According to the Australian Institute of Health and Welfare, from 2015 to 2016, the total health expenditure was USD 181 billion. Out of this, USD 69 billion was spent on hospitals, which is a real increase of USD 2 billion from the previous year. During the same years, non-government sources spent USD 55.8 billion on health.

On the other hand, the Middle East and Africa held least share in the global plasma fractionation market due to inadequate economic development, especially within the African region.

Browse Complete 90 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/plasma-fractionation-market-7397

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Pathological Microscopes Market Revenue, Opportunity, Forecast and Value Chain Analysis 2019

Market Scenario

The growth of the healthcare sector in conjunction with the rising prevalence of diseases is expected to create demand for advanced equipment over the next couple of years. A study conducted by Market Research Future (MRFR) on the pathological microscopes market projects that a CAGR of 4.50% over the assessment period 2018 to 2023. The report further underlines that the market is expected to scale a valuation of USD 523.20 Mn towards the close of 2023.

The increasing burden of diseases such as cancer, diabetes, tuberculosis, etc. is anticipated to intensify the demand for pathological equipment that facilitates early detection and diagnosis. It is projected to pave the way for innovation and development of devices that offer accuracy. This, in turn, is anticipated to have a favorable impact on the growth pattern of the pathological microscopes market in the years to come.

Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/7319

The automation drive witnessed in the laboratories is also projected to accelerate revenue creation for market participants. Again, the increasing count of laboratories and pathology labs are expected to propel the expansion of the pathological microscopes market over the next few years.

Competitive Analysis

Microscope manufacturers in the pathological microscopes market include Nikon Corporation (Japan), Leica Biosystems Nussloch GmbH (Germany), Olympus Corporation (Japan), ZEISS International (Germany), Labomed, Inc. (U.S.), Hitachi High-Technologies Corporation (Japan), Euromex Microscopen BV (The Netherlands), Bruker Corporation (U.S.), Sakura Finetek USA, Inc. (U.S.), and Celestron LLC (U.S.).

The players are focusing on integrating new technologies to expedite the diagnosis rate associated with microscopes and lower the mortality rate. Collaborations, new product launches, and partnerships are strategies being adopted to gain a larger market share.

Segmentation

The pathological microscopes market is segmented by type, application, and end-user.

By type, electron microscope held close to 41.4% share in 2017, followed by optical microscope (18.8%), compound microscope (13.5%), digital microscope (5.4%), fluorescence microscope (4.4%), and others (16.5%). Electron microscopes can generate nearly USD 217.81 million by 2023 owing to their application in life sciences. Prevalence of diseases such as anemia and leukemia which require the need of electron microscopes lend credence to the segment valuation. But digital microscopes can exhibit the highest CAGR of 5.01% during the forecast period to accumulate USD 28.90 million for the pathological microscopes market by 2023.

By end-user, pathology & diagnostic laboratories accounted for 45.2% market share in 2017, followed by hospitals & clinics (38.6%), forensic laboratories (11.5%), and others (4.7%). Hospitals & clinics will be the biggest end-user of the pathological microscopes market by 2023. It can generate USD 206.25 million by the end of the forecast period owing to the setup of various branches of hospital chains to handle high patient volume. On the other hand, pathology & diagnostic laboratories can generate USD 239.73 million by 2023 thanks to possessing various skilled personnel and use of hematology, clinical microbiology, and molecular pathology for rapid diagnosis of diseases.

By application, bodily fluids accounted for 79.4% share of the pathological microscopes market in 2017, followed by tissue scanning (12.7%), and others (7.9%). Bodily fluids can generate USD 418.84 million for the pathological microscopes market by 2023. This can be attributed to use of fluid samples to identify the presence of diseases such as tuberculosis in the human body. High prevalence of blood disorders is driving the segment growth. On the other hand, tissue scanning is touted to accumulate USD 67.94 million by 2023. High prevalence of cancer and use of digital microscopes to detect abnormal tissue growth can fuel the segment growth.

Regional Analysis

The global pathological microscopes market, by region, has been segmented into Americas, Europe, Asia Pacific, and the Middle East & Africa (MEA). Americas is expected to gain control over the maximum market share during the review period. The regional market is projected to touch a valuation of USD 190.98 Mn by the end of 2023. The advancements of laboratories being observed in the region are expected to drive the growth of the pathological microscopes market in the nearby future.

Asia Pacific is projected to exhibit healthy growth owing to the rapid developments in the healthcare sector. The pathological microscopes market in the region is anticipated to attract massive investments over the next couple of years, thus, augmenting the market.

Industry News:

In March 2019, Nikon Instruments Inc., a leader in advanced optical instruments, has announced a partnership with OptraSCAN, On-Demand Digital Pathology Solution Provider, for the launch of OS-15-N, a digital slide scanning system that features Nikon optics.

In January 2019, Roche, a Swiss multinational healthcare company, has announced the introduction of its uPath enterprise software for digital pathology.

Browse Premium Research Report @ https://www.marketresearchfuture.com/reports/pathological-microscopes-market-7319

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Atherectomy Devices Market Dynamics, Forecast, Analysis and Supply Demand 2019

Atherectomy devices are built to either shave, cut, vaporize, laser or sand the plaques. The devices come with different indications. Different atherectomy devices have been invented for commercial use. The location of the plaque and type of blockage influence the choice of atherectomy device to be used. Some atherectomy devices are used only in the larger arteries on the upper portion of the knee, while other devices come with smaller catheters that are suitable for operating the arteries below the knee.

Atherectomy is a technique applied to eliminate atherosclerotic plaque from affected arteries. The plaques are in either peripheral or coronary arterial vasculature and may have distinct characteristics depending on the nature of the plaque. Atherectomy is used widely in cure of both peripheral and coronary arterial ailments. It is a minimally invasive endovascular surgery.

Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/7322

The worldwide Atherectomy devices market is likely to develop remarkably over the forecast period. It is projected that the global atherectomy devices market will register a CAGR of 6.12% over the forecast period of 2018–2023. In 2017, the estimated market value was around 1.09 billion.

The growing rate of peripheral and coronary arterial diseases coupled with increasing demand for minimally invasive techniques is predicted to boost the growth of the atherectomy devices market. Minimally invasive surgical techniques deliver quicker recovery, quick procedural time, lesser risk of infections and complications. The worldwide atherectomy devices market is likely to witness noteable surge in demand due to exponential growth in the incidence of lifestyle-related ailments and elderly population.

Segmentation

The global atherectomy devices market is segmented on the basis of product type, application, and end user.

Based on application, the atherectomy devices market is segmented into cardiovascular, neurovascular, peripheral vascular, and others.

The atherectomy devices market, by product type is categorised into directional atherectomy systems, orbital atherectomy systems, photo-ablative (laser) atherectomy systems, rotational atherectomy systems, and others.

The directional atherectomy systems segment is expected to hold the largest share owing to the high treatment rate, whereas the photo-ablative (laser) atherectomy systems is expected to be the fastest growing segment owing to the growing preference by surgeons.

On the basis of end user, the market is segmented into hospitals, ambulatory surgery centers, and others.

On the basis of region, the global atherectomy devices market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and Latin America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, South Korea, and the rest of Asia-Pacific. The atherectomy devices market in the Middle East and Africa has been segmented into the Middle East and Africa.

Browse Complete 160 Pages Premium Research Report @ https://www.marketresearchfuture.com/reports/atherectomy-devices-market-7322

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Anti-Hypertensive Drugs Market Expected to Boost during 2019 To 2023

This study covers the market dynamics and trends in major countries that are expected to influence the current market scenario and future status of the Global Anti-Hypertensive Drugs Market over the forecast period.

Novartis AG, Daiichi Sankyo Company Limited, Acetelion Ltd, Boehringer Ingelheim, Sanofi S.A., Astra Zeneca plc, Ranbaxy Laboratories Limited, Inc., Takeda Pharmaceuticals Company Limited, Pfizer Inc. are some of the prominent players at the forefront of competition in the Global Market of Anti-Hypertensive Drugs and are profiled in MRFR Analysis.

Get Free Sample Report @ https://www.marketresearchfuture.com/sample_request/2347

According to a recent study report published by the Market Research Future, The global market of Anti-Hypertensive Drugs was valued at $32.2 billion in 2015, and is projected to reach $ USD 41.2 billion by 2023. Thus the market is anticipated to observe a sluggish growth; at a CAGR of 2.73% during 2016 to 2022.

Anti-Hypertensive Drugs are used to treat hypertension (high blood pressure). Hypertension is a state of chronic elevated arterial blood pressure at or greater than 140/90 mm Hg for adults. Hypertension is one of the most powerful risk factors for cardiovascular morbidity and mortality. There exact cause of hypertension is unknown but is said that unhealthy, heady lifestyle and ageing mirror such disorders as “Hypertension”.

The major market driving factors for secondary hypertension are greater detection and early diagnosis. Rise in the prevalence diseases such as kidney problems, thyroid problems, adrenal gland tumours, heart ailments, chronic alcohol use etc. in which anti-hypertensive drugs are used; are some of the other factors driving the growth of the Anti-Hypertensive Drugs market. The constraints however are overwhelming and include patent expiries such as Actelion's Tracleer (2015), and United Therapeutic's Remodulin (2014). Other blockbuster’s such as Novartis's Diovan and Exforge, Sanofi Aventis's Avapro (2012) etc are also off-patent.

Many antihypertensive drugs have their primary action on systemic vascular resistance. Some of these drugs produce vasodilation by interfering with sympathetic adrenergic vascular tone (sympatholytics) or by blocking the formation of angiotensin II or its vascular receptors. Other drugs are direct arterial dilators, and some are mixed arterial and venous dilators. Although less commonly used because of a high incidence of side effects, there are drugs that act on regions in the brain that control sympathetic autonomic outflow. By reducing sympathetic efferent activity, centrally acting drugs decrease arterial pressure by decreasing systemic vascular resistance and cardiac output.

Some antihypertensive drugs, most notably beta-blockers, depress heart rate and contractility (this decreases stroke volume) by blocking the influence of sympathetic nerves on the heart. Calcium-channel blockers, especially those that are more cardioselective, also reduce cardiac output by decreasing heart rate and contractility. Some calcium-channel blockers (most notably the dihydropyridines) are more selective for the systemic vasculature and therefore reduce systemic vascular resistance.

Segmentation

The Anti-Hypertensive Market can be segmented in to 4 key dynamics for the convenience of the report and enhanced understanding;

Segmentation By Pharmacological Class : Comprises Diuretics, ACE Inhibitors, Calcium Channel Blockers, Adrenergic Blocker and other.

Segmentation By Hypertension Type : Comprises Systemic and Pulmonary Hypertension Drugs and other.

Segmentation By Disease Source : Comprises Primary and Secondary.

Segmentation By Regions : Comprises Geographical regions - North America, Europe, APAC and Rest of the World.

Regional Analysis

The antihypertensive drugs market covers growth drivers in the following regions, namely Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA). The Americas accounted for a large market share owing to high prevalence of hypertension linked to cardiovascular and renal disorders. Drives by government and non-government organizations for creating awareness of the medical condition are likely to bolster the revenue of the antihypertensive drugs market in Americas.

The Europe region was the second-largest due to rise of cardiovascular diseases, unhealthy diets, and increase noticed in obesity levels of patients. According to the European Heart Network in 2017, heart diseases accounted for 3.9 million deaths. Germany, France, and the U.K. are expected to be the prime contributors to the antihypertensive drugs market in Europe.

The APAC region is projected to exhibit a robust pace owing to increased healthcare budget and rise in disposable income levels of patients. The setup of research and development centers to fast-track the commoditization of drugs for treating hypertension is likely to boost the APAC antihypertensive drugs market.

Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/anti-hypertensive-drugs-market-2347

About US:

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com